Vendors
日本語
search
  2. //
  3. Reports & insights
  4. //
  5. Maximizing Value in Biotech, Healthtech, Medtech

Maximizing Value in Biotech, Healthtech, Medtech

Create a vendor selection project
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
We are waiting for the vendor to publish their solution profile. Contact us or request the RFX.
Projects allow you to export Registered Vendor details and survey responses for analysis outside of Marsh CND. Please refer to the Marsh CND User Guide for detailed instructions.
Download Registered Vendor Survey responses as PDF
Contact vendor directly with specific questions (ie. pricing, capacity, etc)
8 June 2022

Access to capital, evolving business models, and sustaining innovation were all hot topics that emerged at the 8th LSX World Congress last month in London. The conference, which runs parallel sessions on biotech, healthtech, and medtech, was an opportunity for leaders from across the industry, as well as venture capitalists and financial advisors, to examine ways the industry is moving forward.

A team from Oliver Wyman’s Health and Life Sciences practice was there to engage with peers and lead panel discussions. Below are a few themes we identified from the meeting:

Please click here for the remainder of the post at Oliver Wyman.